The first generic version of Sandostatin ® LAR Depot is now available from Teva Pharmaceuticals. Teva’s Octreotide Acetate for Injectable Suspension is indicated for treatment in patients who have ...
Robert Ramirez, DO, FACP: There have been several advances in neuroendocrine tumor treatment and diagnostics over the last several years. One of the biggest ones is the approval of the Gallium-68 ...
BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study Forty-two patients with advanced thymoma or thymic ...
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today the launch of the first and only generic ...
Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary ...
Please provide your email address to receive an email when new articles are posted on . Diarrhea in cancer patients is common and can result from different treatments and toxicities. These include ...
Background. A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung ...
Available medical therapies for acromegaly are limited by moderate and variable efficacy, the need for life-long monthly intramuscular and/or deep subcutaneous depot, or thrice-daily subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback